A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Phase 1/2 Completed
117 enrolled
Study of DF6215 in Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
215 enrolled 30 charts
SABRINA
Phase 2 Completed
93 enrolled
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Phase 1 Completed
42 enrolled
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
Phase 1/2 Completed
18 enrolled
PICCOLO
Phase 2 Completed
79 enrolled 14 charts
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Phase 1 Completed
86 enrolled 17 charts
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Phase 1 Completed
69 enrolled
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
Phase 2 Completed
25 enrolled 11 charts
Nirogacestat in Ovarian Granulosa Cell Tumors
Phase 2 Completed
53 enrolled
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Phase 1 Completed
6 enrolled
HERGYN
Completed
509 enrolled
A Trial Evaluating TG4050 in Ovarian Carcinoma.
Phase 1 Completed
64 enrolled 14 charts
Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients
Completed
1,018 enrolled
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 2 Completed
178 enrolled 21 charts
MK-4830-002
Phase 2 Completed
160 enrolled 19 charts
OVAL-1
Completed
342 enrolled
Study of ESG401 in Adults With Solid Tumors
Phase 1/2 Completed
156 enrolled
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Phase 3 Completed
421 enrolled
AMPLIFY-201
Phase 1 Completed
25 enrolled 15 charts
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
Phase 2 Completed
29 enrolled
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
87 enrolled 22 charts
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Phase 1 Completed
136 enrolled
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Phase 1/2 Completed
307 enrolled 27 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
OLAP
Completed
661 enrolled
KEYVIBE-005
Phase 2 Completed
613 enrolled
P204
Phase 2 Completed
111 enrolled 22 charts
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Phase 2 Completed
105 enrolled 29 charts
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Completed
7 enrolled
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 Completed
23 enrolled
OPAL
Phase 2 Completed
77 enrolled 8 charts
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients
Phase 3 Completed
252 enrolled
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Phase 1 Completed
285 enrolled
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase 4 Completed
100 enrolled
KANDOVA
Phase 1/2 Completed
18 enrolled
Doxil/Caelyx BE Study
Phase 1 Completed
36 enrolled
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Phase 1 Completed
58 enrolled
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
Phase 3 Completed
574 enrolled
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Phase 1/2 Completed
247 enrolled 15 charts
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Phase 2 Completed
36 enrolled 13 charts
PREFER
Completed
1,429 enrolled
Study of AK112 in the Treatment of Advanced Gynecological Tumors
Phase 2 Completed
53 enrolled
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
Phase 2 Completed
100 enrolled
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Phase 1 Completed
19 enrolled 21 charts